Neil Riordan PhD

Professional Site

  • Scientific Articles
  • Abstracts
  • Stem Cell Research
    • Heart Disease
    • Lupus
    • Mesenchymal Stem Cells
    • Pulmonary
  • Intellectual Property
  • Book Chapters
  • Invited Reviewer
  • Awards
Home Archives for rheumatoid arthritis

Immunomodulation of UCMSC in Rheumatoid Arthritis

Posted on September 26, 2019 Written by nhriordan Leave a Comment

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints: the immune system mistakenly attacks the lining of the joints, causing pain, stiffness and inflammation.

In this pre-clinical study, researchers used a model of RA in rats and injected them with mesenchymal stem cells derived from human umbilical cord (UC-MSC). After assessing the state of their joints following treatment, the animals were dissected to study their levels of inflammatory cytokines, lymphocytes, and other relevant markers, compared to the control group who didn’t receive UC-MSC, and another group who was treated with methotrexate (MTX). The joints of rats treated with UC-MSC did better than those in the other two groups. This, coupled with the fact that UC-MSC were found to regulate inflammatory cytokines as well as MTX in rats, leads the researchers to conclude that UC-MSC may have a broader application prospect than MTX for RA treatment.

Additionally, they extracted blood from 6 RA patients and cultured them in the lab alongside UC-MSC. After observing their interactions, they concluded that that UC-MSC play an immunoregulatory role by balancing Treg/Th17 and inflammatory factors in RA patients.

Treating RA in humans with UC-MSC safely and efficiently is well supported by studies such as this one – we’ll undoubtedly be seeing more articles on this subject in the next months.


Int Immunopharmacol. 2019 Sep;74:105687. doi: 10.1016/j.intimp.2019.105687. Epub 2019 Jul 8.

Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis.

Ma D, Xu K, Zhang G, Liu Y, Gao J, Tian M, Wei C, Li J, Zhang L.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease which is lack of effective therapies. Abnormal activation, proliferation, and differentiation of T lymphocytes are closely related to RA. Mesenchymal stem cells (MSCs) can be used for RA treatment due to their immunoregulatory effects. However, the specific molecular mechanisms have not been fully elucidated and the therapeutic effect has been inconsistent. This study investigated the immunomodulatory effect of human umbilical cord MSCs (hUCMSCs) on T lymphocytes in collagen-induced arthritis (CIA) rats and RA patients to clarify the possible mechanism of hUCMSCs in RA treatment. The effects of hUCMSCs on arthritis index, radiological and synovial pathological changes, T lymphocyte proliferation and apoptosis, RORγt and Foxp3 expression, Th17 and Treg cell ratios, and IL-17 and TGF-β levels were assessed in CIA rats. Further, we verified the effect of hUCMSCs in RA patients, and compared the effect of hUCMSCs with that of hUCMSC derived extracellular vesicles (EVs). The results showed that hUCMSCs inhibited the proliferation and promoted apoptosis in T lymphocytes, downregulated RORγt mRNA and protein expression, decreased Th17 cell ratio, upregulated Foxp3 mRNA and protein expression, and increased Treg cell ratio in the spleen. Furthermore, they downregulated RORγt and Foxp3 expression in the joints, and inhibited IL-17 and promoted TGF-β expression in the serum, thereby improving arthritis, delaying radiological progression, and inhibiting synovial hyperplasia in CIA rats. In vitro the effects of hUCMSCs and EVs were consistent with those in vivo. Therefore, hUCMSCs may be expected to serve as a new therapy for RA.


PMID: 31295689 DOI: 10.1016/j.intimp.2019.105687

Filed Under: Uncategorized Tagged With: mesenchymal stem cells, rheumatoid arthritis, umbilical cord

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis

Posted on January 18, 2014 Written by nhriordan 7 Comments

Press release

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación (CNEI) Institutional Review Board (IRB).

Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Translational Biosciences Logo
Panama City, Panama (PRWEB) January 14, 2014

Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación Institutional Review Board (IRB).
Rheumatoid Arthritis (RA) is an autoimmune disease in which the patient’s immune system generates cellular and antibody responses to various components of the joint such as type I collagen. As a result of this immune response, not only does joint destruction occur, but also other secondary complications such as pulmonary fibrosis, renal damage, and even heart damage. RA affects approximately 0.5-1% of the population in the United States.
Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve RA symptoms. Because they are immune privileged, the recipient’s immune system does not reject them. These properties make MSC interesting candidates for the treatment of rheumatoid arthritis and other autoimmune disorders.
Each patient will receive five intravenous injections of umbilical cord stem cells over the course of 5 days. They will be assessed at 3 months and 12 month primarily for safety and secondarily for indications of efficacy.
The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panama’s 8000 sq. ft. laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.
The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.
“While this is just the first step, it is our hope that Panama’s rapid emergence as a leader in applied stem cell research will lead to safe, effective treatments for debilitating diseases such as rheumatoid arthritis and serve to benefit all Panamanians who suffer from it in the not-too-distant future,” said Ruben Berocal, M.D., National Secretary of Science, Technology and Innovation (SENACYT). “Oversight by the National Committee for Investigational Bioethics ensures patient safety by demanding ethical transparency and compliance with the highest levels of international standards,” he added.
For detailed information about this clinical trial visit http://www.clinicaltrials.gov. If you are a rheumatoid arthritis patient who has not responded to disease modifying anti-rheumatic drugs (DMARD) for at least 6 months you may qualify for this trial. Please email trials(at)translationalbiosciences(dot)com for more information about how to apply.
About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.
Translational Biosciences Web Site: http://www.translationalbiosciences.com
Email: trials(at)translationalbiosciences(dot)com
About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.
Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama
Phone: +507 306-2601
Fax: +507 306-2601
About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases. To-date, the Institute has treated over 2000 patients.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama
Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)
Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)

Filed Under: Uncategorized Tagged With: arthritis, mesenchymal stem cells, Neil Riordan, Panama, rheumatoid, rheumatoid arthritis, riordan, stem cells

Neil Riordan, PhD

  • About Neil Riordan, PhD

Follow me on:

  • Facebook
  • Twitter

Recent Posts

  • Amnion-derived cells for regenerative medicine January 27, 2020
  • Vitrification preserves Wharton’s Jelly up to a year January 21, 2020
  • Adipose MSC for Spinal Cord Injury: ASIA Scores Improvement December 4, 2019
  • UCMSC secretions (exosomes) for Perinatal Brain Injury October 3, 2019
  • Immunomodulation of UCMSC in Rheumatoid Arthritis September 26, 2019

Tags

acute liver failure adipose amnion arthritis CD34 diabetes disease dmd duchenne muscular dystrophy fat Frederick Klenner liver lupus mesenchymal mesenchymal stem cells mitochondria mitochondrial neil Neil Riordan opioid opioid tolerance Panama preeclampsia pregnancy rheumatoid rheumatoid arthritis Richard Davis Humphries Richard Humphries riordan spinal cord injury stem cells umbilical cord vitamin C

Copyright © 2023 · Focus Pro Theme on Genesis Framework · WordPress · Log in